Free Trial

HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare logo
$437.18 +3.64 (+0.84%)
As of 02:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

HCA Healthcare - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
9
Buy
9

Based on 18 Wall Street analysts who have issued ratings for HCA Healthcare in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 9 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for HCA.

Consensus Price Target

$410.83
-6.03% Downside
According to the 18 analysts' twelve-month price targets for HCA Healthcare, the average price target is $410.83. The highest price target for HCA is $445.00, while the lowest price target for HCA is $370.00. The average price target represents a forecasted downside of -6.03% from the current price of $437.19.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for HCA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for HCA Healthcare and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HCA Analyst Ratings Over Time

TypeCurrent Forecast
10/7/24 to 10/7/25
1 Month Ago
9/7/24 to 9/7/25
3 Months Ago
7/9/24 to 7/9/25
1 Year Ago
10/8/23 to 10/7/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
10 Buy rating(s)
14 Buy rating(s)
Hold
9 Hold rating(s)
9 Hold rating(s)
7 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$410.83$401.83$395.71$359.89
Forecasted Upside-6.03% Downside-4.48% Downside4.61% Upside-5.89% Downside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

HCA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HCA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

HCA Healthcare Stock vs. The Competition

TypeHCA HealthcareMedical CompaniesS&P 500
Consensus Rating Score
2.56
2.33
2.51
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside-5.30% Downside1,322.33% Upside170.00% Upside
News Sentiment Rating
Positive News

See Recent HCA News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/7/2025Cantor Fitzgerald
4 of 5 stars
Sarah James
Sarah James
Not Rated
Reiterated RatingOverweight$444.00+2.34%
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingBuy (B-)
9/18/2025Barclays
3 of 5 stars
Andrew Mok
Andrew Mok
Not Rated
Boost TargetOverweight$390.00 ➝ $445.00+11.60%
9/10/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$375.00 ➝ $410.00+3.11%
8/14/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$380.00 ➝ $423.00+8.09%
8/14/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetEqual Weight$385.00 ➝ $375.00-3.76%
8/4/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$360.00 ➝ $370.00+1.89%
7/28/2025Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformPeer Perform
7/28/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$404.00 ➝ $401.00+19.57%
7/28/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetEqual Weight$410.00 ➝ $400.00+19.67%
7/16/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$390.00 ➝ $415.00+15.14%
6/2/2025Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
4/15/2025Baird R W
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
4/9/2025Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral
1/7/2025KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$420.00 ➝ $370.00+20.54%
11/22/2024Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformMarket Perform
10/28/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$450.00 ➝ $440.00+22.05%
10/28/2024Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$390.00 ➝ $400.00+10.22%
8/14/2024UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$405.00 ➝ $438.00+18.74%
7/24/2024Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$367.00 ➝ $396.00+16.32%
6/28/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$359.00 ➝ $375.00+14.85%
1/4/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeOutperformMarket Perform$277.00 ➝ $301.00+9.85%
12/11/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyNeutral$271.00+5.23%
10/25/2023Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$325.00 ➝ $275.00+21.19%
10/25/2023Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$324.00 ➝ $279.00+22.87%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:01 PM ET.


Should I Buy HCA Healthcare Stock? HCA Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, October 5, 2025. Please send any questions or comments about these HCA Healthcare pros and cons to contact@marketbeat.com.

HCA Healthcare
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in HCA Healthcare, Inc.:

  • The current stock price is around $421, reflecting a strong market position and investor interest.
  • HCA Healthcare, Inc. reported impressive earnings, exceeding consensus estimates, which indicates robust financial health and operational efficiency.
  • Institutional ownership is significant, with over 62% of shares held by institutional investors, suggesting confidence in the company's future performance.
  • Recent upgrades in stock ratings from analysts, including a shift to a "buy" rating, indicate positive market sentiment and potential for price appreciation.
  • The company has shown consistent revenue growth, with a year-over-year increase, highlighting its ability to expand and adapt in the healthcare sector.

HCA Healthcare
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in HCA Healthcare, Inc. for these reasons:

  • The stock has experienced fluctuations, with a recent downgrade in ratings, which may signal potential volatility and risk for investors.
  • High debt-to-equity ratio indicates that the company relies significantly on debt financing, which can be a risk factor in economic downturns.
  • Insider selling activity, such as the recent sale of shares by executives, may raise concerns about the company's future prospects from those who are most informed.
  • Despite strong earnings, the company has a negative return on equity, which suggests inefficiencies in generating profit from shareholders' equity.
  • Market competition in the healthcare sector is intense, which could impact HCA Healthcare, Inc.'s market share and profitability in the long term.

HCA Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for HCA Healthcare is $410.83, with a high forecast of $445.00 and a low forecast of $370.00.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HCA Healthcare in the last twelve months. There are currently 9 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HCA shares.

According to analysts, HCA Healthcare's stock has a predicted downside of -6.03% based on their 12-month stock forecasts.

Over the previous 90 days, HCA Healthcare's stock had 2 downgrades by analysts.

Analysts like HCA Healthcare more than other "medical" companies. The consensus rating for HCA Healthcare is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how HCA compares to other companies.


This page (NYSE:HCA) was last updated on 10/7/2025 by MarketBeat.com Staff
From Our Partners